A proposal to meet specific criteria before fully integrating Artificial Intelligence (AI) into the IVF lab.

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
David B Seifer, Charles L Bormann
{"title":"A proposal to meet specific criteria before fully integrating Artificial Intelligence (AI) into the IVF lab.","authors":"David B Seifer, Charles L Bormann","doi":"10.1186/s12958-026-01591-4","DOIUrl":null,"url":null,"abstract":"<p><p>Artificial intelligence (AI) is generating genuine excitement in reproductive medicine for good reason. The promise of more consistent embryo assessment, reduced inter-observer variability, better outcome prediction and meaningful support for the embryologist's judgment represents a real opportunity to improve care for patients who have already invested enormously in the pursuit of a family. Realizing that promise, however, depends on something the field has not always done well which is insisting on rigorous validation before widespread adoption. This editorial is written in that spirit, as advocates for AI who believe the technology's long-term acceptance by patients, clinicians and embryologists will be determined by how carefully we deploy it now and how we proceed going forward. How will we know when AI is ready to fully deploy in the IVF lab? The answer requires distinguishing between being safe and being safe and effective and the medical community has not yet reached consensus on either standard for most applications. Professional societies will need to lead that process. However, in the meantime, with commercial adoption accelerating and stakeholder incentives not always aligned with patient welfare, we propose criteria as a starting framework for that discussion.</p>","PeriodicalId":21011,"journal":{"name":"Reproductive Biology and Endocrinology","volume":"24 1","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13488256/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive Biology and Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12958-026-01591-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Artificial intelligence (AI) is generating genuine excitement in reproductive medicine for good reason. The promise of more consistent embryo assessment, reduced inter-observer variability, better outcome prediction and meaningful support for the embryologist's judgment represents a real opportunity to improve care for patients who have already invested enormously in the pursuit of a family. Realizing that promise, however, depends on something the field has not always done well which is insisting on rigorous validation before widespread adoption. This editorial is written in that spirit, as advocates for AI who believe the technology's long-term acceptance by patients, clinicians and embryologists will be determined by how carefully we deploy it now and how we proceed going forward. How will we know when AI is ready to fully deploy in the IVF lab? The answer requires distinguishing between being safe and being safe and effective and the medical community has not yet reached consensus on either standard for most applications. Professional societies will need to lead that process. However, in the meantime, with commercial adoption accelerating and stakeholder incentives not always aligned with patient welfare, we propose criteria as a starting framework for that discussion.

在将人工智能(AI)完全整合到试管婴儿实验室之前,应满足特定标准的建议。
人工智能(AI)在生殖医学领域引起真正的兴奋是有充分理由的。更一致的胚胎评估,减少观察者之间的差异,更好的结果预测和对胚胎学家判断的有意义的支持的承诺代表了一个真正的机会,可以改善对那些已经在追求家庭方面投入了巨大资金的患者的护理。然而,实现这一承诺取决于该领域并不总是做得很好的一些事情,即在广泛采用之前坚持严格的验证。这篇社论就是本着这种精神写的,作为人工智能的倡导者,他们认为,这项技术能否被患者、临床医生和胚胎学家长期接受,将取决于我们现在如何谨慎地部署它,以及我们如何向前推进。我们如何知道人工智能何时准备好全面部署在试管婴儿实验室?答案需要区分安全与安全有效之间的区别,而医学界尚未就大多数应用中的任何一个标准达成共识。专业协会将需要引领这一进程。然而,与此同时,随着商业应用的加速以及利益相关者的激励并不总是与患者的福利相一致,我们提出了一些标准作为讨论的开始框架。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Reproductive Biology and Endocrinology
Reproductive Biology and Endocrinology 医学-内分泌学与代谢
CiteScore
7.90
自引率
2.30%
发文量
161
审稿时长
4-8 weeks
期刊介绍: Reproductive Biology and Endocrinology publishes and disseminates high-quality results from excellent research in the reproductive sciences. The journal publishes on topics covering gametogenesis, fertilization, early embryonic development, embryo-uterus interaction, reproductive development, pregnancy, uterine biology, endocrinology of reproduction, control of reproduction, reproductive immunology, neuroendocrinology, and veterinary and human reproductive medicine, including all vertebrate species.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书